Autism Spectrum Disorder (ASD) is a complex syndrome with a plethora of clinical manifestations. Although such variability may be attributable to diverse genetic and epigenetic factors, mesolimbic dopaminergic reward pathways are consistently implicated in the illness’ course and neuropathobiology pointing to a need in an updated perspective on such a potential overlap area. To that end, we introduce a structured framework dissecting ASD's pathophysiology into stages while emphasizing the involvement of the classical reward structures. Through data mining of Genome-Wide Association Studies (GWAS) and in silico analyses, we uncovered genetic and epigenetic markers pointing to Reward Deficiency Syn-drome (RDS) component of ASD. We employ innovative approaches, including protein-protein interactions, gene regulatory networks, and systems biology analyses, to identify pathways and ASD gene ontologies. The multi-omics analysis integrates findings across genomics, proteomics, metabolomics, and phenomics, reinforcing the concept of ASD as an endophenotype of RDS. This comprehensive approach offers new insights into the genetic architecture and molecular mechanisms of ASD, paving the way for personalized medicine strategies thus yielding novel therapeutic interventions.
Background: GLP‑1 receptor agonists (GLP‑1RAs) are effective for type 2 diabetes and obesity and engage central stress and reward pathways (HPA axis; mesolimbic dopamine). Psychiatric signals have been reported in some settings. Objective :To narratively synthesize evidence on neuropsychiatric effects of GLP‑1RAs—mood, anxiety, suicidality, reward processing, substance use, and migraine—and to consider genetic/epigenetic moderators (e.g., hypodopaminergia/reward deficiency syndrome).Evidence: Mechanistic and imaging studies demonstrate GLP‑1 engagement of HPA and reward circuitry; animal work suggests acute anxiogenic responses with mixed chronic effects. Pharmacovigilance datasets (FAERS/EudraVigilance) show signals for headache, dizziness, sensory changes, and less consistently for depression/anxiety/suicidality; such data are hypothesis‑generating and not causal. Clinical trials and meta‑analyses report heterogeneous outcomes, including small antidepressant effects in some T2DM cohorts. Conclusions: Neuropsychiatric outcomes with GLP‑1RAs appear context‑dependent. Individuals with hypodopaminergic biology may be vulnerable to reward blunting/anxiety, whereas others may experience mood benefits. A pragmatic approach is screen–stratify–monitor, with slow titration and prompt adjustment if psychiatric signals emerge. Prospective, genotype‑informed studies are needed to identify who benefits or is harmed and why.